Hereditary Angioedema Therapeutics Market by Treatment Type (On Demand, Prophylaxis), Drug Class (Bradykinin Receptor Antagonist, Kallikrein Inhibitor, Monoclonal Antibody), Route Of Administration, Distribution Channel, End User - Global Forecast 2025-20
Description
The Hereditary Angioedema Therapeutics Market was valued at USD 38.29 billion in 2024 and is projected to grow to USD 40.77 billion in 2025, with a CAGR of 6.45%, reaching USD 63.15 billion by 2032.
A high-level primer on the evolving hereditary angioedema therapeutic ecosystem emphasizing clinical advances, delivery innovations, and strategic tensions for stakeholders
Hereditary angioedema therapeutics occupy a distinct niche at the intersection of rare-disease medicine, biologics innovation, and evolving patient-centric care models. Recent years have seen a maturation of both acute and prophylactic approaches, accompanied by expanded treatment modalities and administration routes that address diverse patient needs. As a result, stakeholders across clinical, regulatory, payer, and manufacturing domains are recalibrating priorities to capture clinical value, operational resilience, and sustainable access.
This introduction frames the therapeutic landscape by outlining clinical advances, shifts in delivery models, and the strategic tensions that define near-term decision making. It highlights how innovation in drug classes and administration routes has reshaped patient expectations and created new commercial dynamics. In doing so, it sets the stage for deeper analysis of transformative shifts, policy impacts, segmentation realities, regional nuances, and the competitive moves that will determine future leadership in this therapeutic area.
How shifts in prophylactic adoption, administration innovations, payer value demands, and supply chain resilience are reshaping clinical practice and commercial strategy
The hereditary angioedema therapeutic landscape is undergoing a set of transformative shifts that are rewriting clinical practice and commercial playbooks. First, the clinical paradigm is moving beyond episodic symptom control toward sustained prophylaxis for a growing segment of patients, driven by better-tolerated biologics and the emergence of oral small molecules. This transition is reshaping care pathways and reallocating clinical resources, with implications for prescribing behavior and patient monitoring.
Second, administration innovations are enabling a migration from exclusively clinic-based infusion models to more flexible subcutaneous and oral regimens that support home-based care. These advances reduce treatment burden and open new channels for distribution and support services. Third, payer engagement is intensifying around real-world outcomes and value-based arrangements, prompting manufacturers to invest in evidence generation and patient support programs. Finally, supply chain and manufacturing considerations are increasingly strategic drivers, as plasma-sourced therapies and complex biologics require resilient sourcing, cold-chain logistics, and localized manufacturing strategies. Taken together, these shifts create multiple vectors for competitive differentiation and collaboration across the ecosystem.
Assessment of how cumulative tariff measures announced through 2025 amplify supply chain risk, cost pressures, and strategic manufacturing choices across the therapeutic value chain
Potential tariff policy changes and trade measures announced or implemented through 2025 have introduced a layer of cost and operational uncertainty that cascades across the hereditary angioedema therapeutics value chain. Tariffs on imported raw materials, active pharmaceutical ingredients, and finished biologic products can raise landed costs for manufacturers that rely on global supply networks, particularly for plasma-derived medicines and specialized reagents used in recombinant manufacturing. In turn, these cost pressures influence pricing strategy, supplier selection, and decisions about nearshoring production capacity.
Beyond direct cost effects, tariffs can alter sourcing timelines and logistics complexity, increasing the risk of supply disruptions for therapies that depend on limited plasma pools or niche manufacturing capabilities. This dynamic encourages manufacturers to diversify supplier bases and consider investment in regional manufacturing or fill-and-finish capabilities to mitigate exposure. From a payer and provider perspective, cumulative tariff impacts may accelerate conversations about therapeutic substitution, formulary management, and contracting approaches that better reflect long-term total cost of care. In summary, tariffs amplify the need for strategic supply chain planning, contractual flexibility, and outcome-focused evidence to preserve access while protecting margins.
In-depth segmentation insights revealing how treatment type, drug class, administration routes, distribution networks, and end-use settings jointly shape access and adoption dynamics
Segmentation analysis of hereditary angioedema therapeutics reveals important heterogeneity in clinical use, commercial dynamics, and patient experience that should inform product positioning and go-to-market planning. When examined by treatment type, the landscape bifurcates into on-demand therapies and prophylactic regimens. On-demand interventions include bradykinin receptor antagonists, kallikrein inhibitors, plasma-derived C1 inhibitors, and recombinant C1 inhibitors, each offering different onset-of-action, administration settings, and clinical use cases. Prophylactic strategies encompass monoclonal antibodies, oral small molecules, and plasma-derived C1 inhibitors, which vary in dosing frequency, route of administration, and long-term tolerability considerations.
Looking through the lens of drug class, differentiation emerges across bradykinin receptor antagonists, kallikrein inhibitors, monoclonal antibodies, plasma-derived C1 inhibitors, and recombinant C1 inhibitors, with each class presenting distinct manufacturing footprints, regulatory pathways, and value propositions. Route of administration further segments clinical adoption and patient preference; intravenous dosing remains important for hospital-based acute care, oral therapies offer convenience and potential adherence benefits, and subcutaneous options enable home administration and reduced healthcare utilization. Distribution channel segmentation across hospital pharmacies, retail pharmacies, and specialty pharmacies affects access models, patient support infrastructure, and reimbursement workflows. Finally, end-user segmentation-clinic, home care, and hospital-captures different care settings' operational needs and influences on adherence, monitoring, and support services. Integrating these segmentation perspectives provides a granular framework to prioritize clinical evidence generation, distribution partnerships, and patient support investments that match product characteristics to real-world care pathways.
Comparative regional dynamics and access considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory strategy and market entry
Regional dynamics materially influence clinical practice patterns, regulatory engagement, reimbursement pathways, and supply chain design for hereditary angioedema therapeutics. In the Americas, established rare-disease infrastructure, broad payer coverage in some markets, and a history of biologics adoption create fertile ground for both prophylactic and on-demand innovations. This environment supports rapid uptake for therapies that demonstrate clear quality-of-life benefits, while also driving intense payer scrutiny of long-term value.
In Europe, the Middle East & Africa region, regulatory heterogeneity and divergent reimbursement frameworks mean market entry strategies must be tailored to national systems, with an emphasis on health technology assessment evidence and local clinical advocacy. Access timelines and pricing pressure vary substantially across these markets. In the Asia-Pacific region, growing investment in rare-disease care and expanding hospital capacity are increasing demand for modern therapeutics, but manufacturers must navigate varied regulatory pathways, manufacturing localization expectations, and different distribution channel ecosystems. Across all regions, strategic choices about local manufacturing, partnerships with specialty pharmacies or distributors, and evidence generation priorities will determine the pace and scale of commercial penetration.
Competitive and collaborative dynamics where established biologics expertise meets emerging small-molecule innovators to redefine treatment sequencing and commercial positioning
The competitive and collaborative landscape in hereditary angioedema therapeutics reflects a blend of established biologics manufacturers, specialty rare-disease firms, and emerging small-molecule innovators. Incumbent plasma and recombinant product providers continue to leverage deep clinical experience, extensive safety databases, and established distribution relationships to defend therapeutic positions. Meanwhile, companies developing monoclonal antibodies and oral kallikrein inhibitors are forcing a reassessment of treatment sequencing by offering longer-duration prophylaxis or more convenient administration.
Newer entrants and mid-sized biotechs are driving innovation in oral formulations and subcutaneous delivery systems, which in turn pressures legacy players to optimize patient support, demonstrate real-world effectiveness, and streamline cost-to-serve. Strategic partnerships, licensing deals, and targeted acquisitions are likely to accelerate as companies seek complementary capabilities in biologics manufacturing, patient support platforms, and payer contracting. For stakeholders evaluating competitive positioning, the priority is to map product differentiation to operational capabilities and to anticipate where consolidation or strategic alliances could reshape access and commercial momentum.
Practical and prioritized strategic recommendations for manufacturers and stakeholders to strengthen evidence, supply resilience, patient support, and payer alignment in this therapeutic area
Industry leaders should pursue a pragmatic set of actions to capture clinical value while protecting access and operational resilience. First, prioritize evidence-generation strategies that link therapy use to tangible outcomes valued by payers and clinicians, such as reductions in attack frequency, emergency resource utilization, and demonstrable quality-of-life improvements. Robust real-world evidence programs that incorporate patient-reported outcomes and digital monitoring will strengthen contracting conversations and support differentiated positioning.
Second, invest in supply chain de-risking by diversifying suppliers, evaluating regional manufacturing or fill-and-finish capacity, and building scenario plans for tariff or trade disruptions. Third, align commercial and medical affairs strategies to support home-based care adoption through education, nurse support models, and integrated adherence tools that ease the transition from clinic infusions to subcutaneous or oral regimens. Fourth, pursue adaptive pricing and contracting approaches, including outcomes-based arrangements where appropriate, to address payer concerns while sharing risk. Finally, consider targeted partnerships or M&A to acquire capabilities in patient support, specialty distribution, or novel delivery technologies that accelerate adoption and reduce time to value realization.
Transparent mixed-methods research approach integrating primary expert interviews, regulatory and clinical literature review, and scenario analysis to produce actionable insights for stakeholders
This research synthesizes regulatory reviews, peer-reviewed clinical literature, product labeling, public company disclosures, and interviews with clinical and commercial experts to produce an integrated view of the hereditary angioedema therapeutic landscape. Primary research included structured consultations with clinicians experienced in rare-disease management, specialty pharmacy leaders, and supply chain experts to validate observed trends and surface practical implementation considerations. Secondary research incorporated a systematic review of recent approvals, guideline updates, and published outcomes studies to ensure clinical accuracy and contextual relevance.
Analytical methods combined qualitative thematic analysis with comparative assessment across drug classes, administration routes, distribution channels, and end-user settings. Scenario-based supply chain and policy impact modeling were used to explore the operational implications of tariff changes and manufacturing localization. Throughout the methodology, emphasis was placed on triangulating insights from multiple sources and prioritizing actionable intelligence over descriptive reporting. The result is a pragmatic framework designed to inform commercial strategy, clinical engagement, and operational planning without reliance on proprietary or single-source assumptions.
Synthesis of clinical innovation, operational imperatives, and strategic priorities that highlights where focused action will deliver improved access and durable competitive advantage
The hereditary angioedema therapeutics landscape is at an inflection point where clinical innovation, administration convenience, and strategic commercial choices intersect to determine long-term impact on patients and payers. Advances in prophylactic options and the maturation of oral and subcutaneous administration routes are expanding treatment possibilities and demanding new approaches to evidence generation, distribution, and patient support. At the same time, external pressures-such as potential tariff shifts and supply chain fragility-require proactive mitigation and flexible manufacturing strategies.
Looking ahead, the winners will be organizations that align differentiated clinical value with pragmatic operational execution: those that can demonstrate meaningful outcomes, enable home-based care, and secure resilient access pathways. Integrating the segmentation, regional, and competitive insights presented here should guide prioritization of investment and partnership choices that maximize both patient benefit and commercial viability. This conclusion underscores the importance of timely strategic action informed by rigorous, cross-functional analysis.
Note: PDF & Excel + Online Access - 1 Year
A high-level primer on the evolving hereditary angioedema therapeutic ecosystem emphasizing clinical advances, delivery innovations, and strategic tensions for stakeholders
Hereditary angioedema therapeutics occupy a distinct niche at the intersection of rare-disease medicine, biologics innovation, and evolving patient-centric care models. Recent years have seen a maturation of both acute and prophylactic approaches, accompanied by expanded treatment modalities and administration routes that address diverse patient needs. As a result, stakeholders across clinical, regulatory, payer, and manufacturing domains are recalibrating priorities to capture clinical value, operational resilience, and sustainable access.
This introduction frames the therapeutic landscape by outlining clinical advances, shifts in delivery models, and the strategic tensions that define near-term decision making. It highlights how innovation in drug classes and administration routes has reshaped patient expectations and created new commercial dynamics. In doing so, it sets the stage for deeper analysis of transformative shifts, policy impacts, segmentation realities, regional nuances, and the competitive moves that will determine future leadership in this therapeutic area.
How shifts in prophylactic adoption, administration innovations, payer value demands, and supply chain resilience are reshaping clinical practice and commercial strategy
The hereditary angioedema therapeutic landscape is undergoing a set of transformative shifts that are rewriting clinical practice and commercial playbooks. First, the clinical paradigm is moving beyond episodic symptom control toward sustained prophylaxis for a growing segment of patients, driven by better-tolerated biologics and the emergence of oral small molecules. This transition is reshaping care pathways and reallocating clinical resources, with implications for prescribing behavior and patient monitoring.
Second, administration innovations are enabling a migration from exclusively clinic-based infusion models to more flexible subcutaneous and oral regimens that support home-based care. These advances reduce treatment burden and open new channels for distribution and support services. Third, payer engagement is intensifying around real-world outcomes and value-based arrangements, prompting manufacturers to invest in evidence generation and patient support programs. Finally, supply chain and manufacturing considerations are increasingly strategic drivers, as plasma-sourced therapies and complex biologics require resilient sourcing, cold-chain logistics, and localized manufacturing strategies. Taken together, these shifts create multiple vectors for competitive differentiation and collaboration across the ecosystem.
Assessment of how cumulative tariff measures announced through 2025 amplify supply chain risk, cost pressures, and strategic manufacturing choices across the therapeutic value chain
Potential tariff policy changes and trade measures announced or implemented through 2025 have introduced a layer of cost and operational uncertainty that cascades across the hereditary angioedema therapeutics value chain. Tariffs on imported raw materials, active pharmaceutical ingredients, and finished biologic products can raise landed costs for manufacturers that rely on global supply networks, particularly for plasma-derived medicines and specialized reagents used in recombinant manufacturing. In turn, these cost pressures influence pricing strategy, supplier selection, and decisions about nearshoring production capacity.
Beyond direct cost effects, tariffs can alter sourcing timelines and logistics complexity, increasing the risk of supply disruptions for therapies that depend on limited plasma pools or niche manufacturing capabilities. This dynamic encourages manufacturers to diversify supplier bases and consider investment in regional manufacturing or fill-and-finish capabilities to mitigate exposure. From a payer and provider perspective, cumulative tariff impacts may accelerate conversations about therapeutic substitution, formulary management, and contracting approaches that better reflect long-term total cost of care. In summary, tariffs amplify the need for strategic supply chain planning, contractual flexibility, and outcome-focused evidence to preserve access while protecting margins.
In-depth segmentation insights revealing how treatment type, drug class, administration routes, distribution networks, and end-use settings jointly shape access and adoption dynamics
Segmentation analysis of hereditary angioedema therapeutics reveals important heterogeneity in clinical use, commercial dynamics, and patient experience that should inform product positioning and go-to-market planning. When examined by treatment type, the landscape bifurcates into on-demand therapies and prophylactic regimens. On-demand interventions include bradykinin receptor antagonists, kallikrein inhibitors, plasma-derived C1 inhibitors, and recombinant C1 inhibitors, each offering different onset-of-action, administration settings, and clinical use cases. Prophylactic strategies encompass monoclonal antibodies, oral small molecules, and plasma-derived C1 inhibitors, which vary in dosing frequency, route of administration, and long-term tolerability considerations.
Looking through the lens of drug class, differentiation emerges across bradykinin receptor antagonists, kallikrein inhibitors, monoclonal antibodies, plasma-derived C1 inhibitors, and recombinant C1 inhibitors, with each class presenting distinct manufacturing footprints, regulatory pathways, and value propositions. Route of administration further segments clinical adoption and patient preference; intravenous dosing remains important for hospital-based acute care, oral therapies offer convenience and potential adherence benefits, and subcutaneous options enable home administration and reduced healthcare utilization. Distribution channel segmentation across hospital pharmacies, retail pharmacies, and specialty pharmacies affects access models, patient support infrastructure, and reimbursement workflows. Finally, end-user segmentation-clinic, home care, and hospital-captures different care settings' operational needs and influences on adherence, monitoring, and support services. Integrating these segmentation perspectives provides a granular framework to prioritize clinical evidence generation, distribution partnerships, and patient support investments that match product characteristics to real-world care pathways.
Comparative regional dynamics and access considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory strategy and market entry
Regional dynamics materially influence clinical practice patterns, regulatory engagement, reimbursement pathways, and supply chain design for hereditary angioedema therapeutics. In the Americas, established rare-disease infrastructure, broad payer coverage in some markets, and a history of biologics adoption create fertile ground for both prophylactic and on-demand innovations. This environment supports rapid uptake for therapies that demonstrate clear quality-of-life benefits, while also driving intense payer scrutiny of long-term value.
In Europe, the Middle East & Africa region, regulatory heterogeneity and divergent reimbursement frameworks mean market entry strategies must be tailored to national systems, with an emphasis on health technology assessment evidence and local clinical advocacy. Access timelines and pricing pressure vary substantially across these markets. In the Asia-Pacific region, growing investment in rare-disease care and expanding hospital capacity are increasing demand for modern therapeutics, but manufacturers must navigate varied regulatory pathways, manufacturing localization expectations, and different distribution channel ecosystems. Across all regions, strategic choices about local manufacturing, partnerships with specialty pharmacies or distributors, and evidence generation priorities will determine the pace and scale of commercial penetration.
Competitive and collaborative dynamics where established biologics expertise meets emerging small-molecule innovators to redefine treatment sequencing and commercial positioning
The competitive and collaborative landscape in hereditary angioedema therapeutics reflects a blend of established biologics manufacturers, specialty rare-disease firms, and emerging small-molecule innovators. Incumbent plasma and recombinant product providers continue to leverage deep clinical experience, extensive safety databases, and established distribution relationships to defend therapeutic positions. Meanwhile, companies developing monoclonal antibodies and oral kallikrein inhibitors are forcing a reassessment of treatment sequencing by offering longer-duration prophylaxis or more convenient administration.
Newer entrants and mid-sized biotechs are driving innovation in oral formulations and subcutaneous delivery systems, which in turn pressures legacy players to optimize patient support, demonstrate real-world effectiveness, and streamline cost-to-serve. Strategic partnerships, licensing deals, and targeted acquisitions are likely to accelerate as companies seek complementary capabilities in biologics manufacturing, patient support platforms, and payer contracting. For stakeholders evaluating competitive positioning, the priority is to map product differentiation to operational capabilities and to anticipate where consolidation or strategic alliances could reshape access and commercial momentum.
Practical and prioritized strategic recommendations for manufacturers and stakeholders to strengthen evidence, supply resilience, patient support, and payer alignment in this therapeutic area
Industry leaders should pursue a pragmatic set of actions to capture clinical value while protecting access and operational resilience. First, prioritize evidence-generation strategies that link therapy use to tangible outcomes valued by payers and clinicians, such as reductions in attack frequency, emergency resource utilization, and demonstrable quality-of-life improvements. Robust real-world evidence programs that incorporate patient-reported outcomes and digital monitoring will strengthen contracting conversations and support differentiated positioning.
Second, invest in supply chain de-risking by diversifying suppliers, evaluating regional manufacturing or fill-and-finish capacity, and building scenario plans for tariff or trade disruptions. Third, align commercial and medical affairs strategies to support home-based care adoption through education, nurse support models, and integrated adherence tools that ease the transition from clinic infusions to subcutaneous or oral regimens. Fourth, pursue adaptive pricing and contracting approaches, including outcomes-based arrangements where appropriate, to address payer concerns while sharing risk. Finally, consider targeted partnerships or M&A to acquire capabilities in patient support, specialty distribution, or novel delivery technologies that accelerate adoption and reduce time to value realization.
Transparent mixed-methods research approach integrating primary expert interviews, regulatory and clinical literature review, and scenario analysis to produce actionable insights for stakeholders
This research synthesizes regulatory reviews, peer-reviewed clinical literature, product labeling, public company disclosures, and interviews with clinical and commercial experts to produce an integrated view of the hereditary angioedema therapeutic landscape. Primary research included structured consultations with clinicians experienced in rare-disease management, specialty pharmacy leaders, and supply chain experts to validate observed trends and surface practical implementation considerations. Secondary research incorporated a systematic review of recent approvals, guideline updates, and published outcomes studies to ensure clinical accuracy and contextual relevance.
Analytical methods combined qualitative thematic analysis with comparative assessment across drug classes, administration routes, distribution channels, and end-user settings. Scenario-based supply chain and policy impact modeling were used to explore the operational implications of tariff changes and manufacturing localization. Throughout the methodology, emphasis was placed on triangulating insights from multiple sources and prioritizing actionable intelligence over descriptive reporting. The result is a pragmatic framework designed to inform commercial strategy, clinical engagement, and operational planning without reliance on proprietary or single-source assumptions.
Synthesis of clinical innovation, operational imperatives, and strategic priorities that highlights where focused action will deliver improved access and durable competitive advantage
The hereditary angioedema therapeutics landscape is at an inflection point where clinical innovation, administration convenience, and strategic commercial choices intersect to determine long-term impact on patients and payers. Advances in prophylactic options and the maturation of oral and subcutaneous administration routes are expanding treatment possibilities and demanding new approaches to evidence generation, distribution, and patient support. At the same time, external pressures-such as potential tariff shifts and supply chain fragility-require proactive mitigation and flexible manufacturing strategies.
Looking ahead, the winners will be organizations that align differentiated clinical value with pragmatic operational execution: those that can demonstrate meaningful outcomes, enable home-based care, and secure resilient access pathways. Integrating the segmentation, regional, and competitive insights presented here should guide prioritization of investment and partnership choices that maximize both patient benefit and commercial viability. This conclusion underscores the importance of timely strategic action informed by rigorous, cross-functional analysis.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
199 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Emergence of gene therapy candidates aiming to provide durable control of hereditary angioedema attacks
- 5.2. Expansion of real world evidence studies evaluating long term safety and efficacy of prophylactic therapies
- 5.3. Increasing focus on patient centric outcome measures and quality of life in clinical trial design
- 5.4. Integration of online treatment dispensing platforms to streamline home administration of HAE therapies
- 5.5. Pricing pressure and evolving reimbursement policies impacting access to novel hereditary angioedema treatments
- 5.6. Development of next generation monoclonal antibodies with extended half life for acute HAE episode prevention
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Hereditary Angioedema Therapeutics Market, by Treatment Type
- 8.1. On Demand
- 8.1.1. Bradykinin Receptor Antagonist
- 8.1.2. Kallikrein Inhibitor
- 8.1.3. Plasma Derived C1 Inhibitor
- 8.1.4. Recombinant C1 Inhibitor
- 8.2. Prophylaxis
- 8.2.1. Monoclonal Antibody
- 8.2.2. Oral Small Molecule
- 8.2.3. Plasma Derived C1 Inhibitor
- 9. Hereditary Angioedema Therapeutics Market, by Drug Class
- 9.1. Bradykinin Receptor Antagonist
- 9.2. Kallikrein Inhibitor
- 9.3. Monoclonal Antibody
- 9.4. Plasma Derived C1 Inhibitor
- 9.5. Recombinant C1 Inhibitor
- 10. Hereditary Angioedema Therapeutics Market, by Route Of Administration
- 10.1. Intravenous
- 10.2. Oral
- 10.3. Subcutaneous
- 11. Hereditary Angioedema Therapeutics Market, by Distribution Channel
- 11.1. Hospital Pharmacies
- 11.2. Retail Pharmacies
- 11.3. Online Pharmacies
- 12. Hereditary Angioedema Therapeutics Market, by End User
- 12.1. Clinic
- 12.2. Home Care
- 12.3. Hospital
- 13. Hereditary Angioedema Therapeutics Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Hereditary Angioedema Therapeutics Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Hereditary Angioedema Therapeutics Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Apellis Pharmaceuticals, Inc.
- 16.3.2. Attune Pharmaceuticals, Inc.
- 16.3.3. Biocryst Pharmaceuticals, Inc.
- 16.3.4. BioMarin Pharmaceutical Inc.
- 16.3.5. CSL Behring LLC
- 16.3.6. Ionis Pharmaceuticals, Inc.
- 16.3.7. KalVista Pharmaceuticals, Inc.
- 16.3.8. Novartis AG
- 16.3.9. Pharming Group N.V.
- 16.3.10. Sanofi S.A.
- 16.3.11. Takeda Pharmaceutical Company Limited
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
